IHC
Microenvironments Give Clues to Distinct Immunotherapy Responses in Brain Metastases, Glioblastomas
Investigators found microenvironment differences in checkpoint blockade immunotherapy-treated cases involving brain metastases versus recurrent glioblastoma.
Companies that built their business in tissue and blood-based DNA analyses are now exploring imaging technologies across a variety of fronts.
End-Stage Ovarian Cancer Marked by Rampant Treatment Resistance, Multiple Clones
By profiling multiple tumors per patient, researchers found pronounced polyclonal disease and diverse resistance mechanisms in end-stage high-grade serous ovarian carcinoma.
Gastric Cancer Chemotherapy Response, Prognoses Predicted With Blood-Based Immune Proteomics
By analyzing blood serum proteomics alongside gastric tumors' omics profiles, researchers found immune features coinciding with treatment response and survival.
NeoGenomics, ImmunoGen Ink Testing Deal for Newly Approved Folate Receptor Drug
The pharma firm will cover the cost for eligible ovarian cancer patients to be tested using the companion diagnostic to its new drug Elahere.